Zydus Lifesciences is preparing for a major international expansion of its semaglutide business, with plans to roll out the drug across more than 20 markets over the next two years. The company is also betting on a sharp scale-up of its biosimil...
HAB Pharma targets Rs 3,000 crore revenue by 2030 as the pharmaceutical company moves ahead with an ambitious expansion strategy following its merger with Signature Phytochemical Industries. The deal marks a major step in HAB Pharma growth strateg...
Bayer is deepening its India self-care market push as the global pharmaceutical company bets on rising demand for preventive healthcare and over-the-counter wellness products to strengthen its position in one of its fastest-growing markets.
The Indian Patent Office has refused to grant US pharmaceutical firm AbbVie a Hepatitis C patent for its combination therapy glecaprevir/pibrentasvir, marketed globally as Mavyret.
Indian pharma firms post strong FY26 revenue growth as major companies across the pharmaceutical and healthcare sectors reported solid sales expansion, strong Q4 recoveries, and improving operational performance.
As India grapples with rising temperatures, the Centre-issued heat advisory recommending AYUSH remedies aims to help citizens stay safe from heat stress and heat-related illnesses.
Calpol has long been a trusted name in Indian households, especially among parents looking for quick fever and pain relief for children. Now, Calpol has received one of the strongest forms of legal recognition in India after the Delhi High Court...
Reporting its fourth quarter results for FY 26, Zydus Wellness, reported a consolidated growth of 62.1% in Net Sales which stood at Rs. 14,761 million as compared to Rs. 9,106 million in the corresponding period of the previous year.
Strides Pharma Science Ltd today announced its consolidated financial results for the quarter (Q4FY26) and Full Year (FY26) ended March 31, 2026. Badree Komandur, MD & Group CEO, commented on the performance and said, “Strides continued to deliver...
India’s pharmaceutical industry is under pressure as rising costs and an export slump squeeze drugmakers hard, impacting profits and slowing growth. Pharmaceutical companies, which have long benefited from strong overseas demand, are now facin...
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")